{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T05:14:30Z","timestamp":1791522870725,"version":"4.3.4"},"reference-count":252,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T00:00:00Z","timestamp":1768780800000},"content-version":"vor","delay-in-days":2241,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2020,1,29]],"date-time":"2020-01-29T00:00:00Z","timestamp":1580256000000},"content-version":"vor","delay-in-days":59,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2019,12,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Heart failure (HF) remains a major cause of mortality, morbidity, and poor quality of life. It is an area of active research. This article is aimed to give an update on recent advances in all aspects of this syndrome. Major changes occurred in drug treatment of HF with reduced ejection fraction (HFrEF). Sacubitril\/valsartan is indicated as a substitute to ACEi\/ARBs after PARADIGM-HF (hazard ratio [HR], 0.80; 95% confidence interval [CI], 0.73 to 0.87 for sacubitril\/valsartan vs. enalapril for the primary endpoint and Wei, Lin and Weissfeld HR 0.79, 95% CI 0.71\u20130.89 for recurrent events). Its initiation was then shown as safe and potentially useful in recent studies in patients hospitalized for acute HF. More recently, dapagliflozin and prevention of adverse-outcomes in DAPA-HF trial showed the beneficial effects of the sodium\u2013glucose transporter type 2 inhibitor dapaglifozin vs. placebo, added to optimal standard therapy [HR, 0.74; 95% CI, 0.65 to 0.85;0.74; 95% CI, 0.65 to 0.85 for the primary endpoint]. Trials with other SGLT 2 inhibitors and in other patients, such as those with HF with preserved ejection fraction (HFpEF) or with recent decompensation, are ongoing. Multiple studies showed the unfavourable prognostic significance of abnormalities in serum potassium levels. Potassium lowering agents may allow initiation and titration of mineralocorticoid antagonists in a larger proportion of patients. Meta-analyses suggest better outcomes with ferric carboxymaltose in patients with iron deficiency. Drugs effective in HFrEF may be useful also in HF with mid-range ejection fraction. Better diagnosis and phenotype characterization seem warranted in HF with preserved ejection fraction. These and other burning aspects of HF research are summarized and reviewed in this article.<\/jats:p>","DOI":"10.1002\/ehf2.12555","type":"journal-article","created":{"date-parts":[[2020,1,29]],"date-time":"2020-01-29T20:38:55Z","timestamp":1580330335000},"page":"1105-1127","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":206,"title":["Highlights in Heart Failure"],"prefix":"10.1093","volume":"6","author":[{"given":"Daniela","family":"Tomasoni","sequence":"first","affiliation":[{"name":"Cardiology, Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, University of Brescia, Cardiothoracic Department, Civil Hospitals , Brescia ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianna","family":"Adamo","sequence":"additional","affiliation":[{"name":"Cardiology, Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, University of Brescia, Cardiothoracic Department, Civil Hospitals , Brescia ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo Mario","family":"Lombardi","sequence":"additional","affiliation":[{"name":"Cardiology, Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, University of Brescia, Cardiothoracic Department, Civil Hospitals , Brescia ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6691-8568","authenticated-orcid":false,"given":"Marco","family":"Metra","sequence":"additional","affiliation":[{"name":"Cardiology, Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, University of Brescia, Cardiothoracic Department, Civil Hospitals , Brescia ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,1,29]]},"reference":[{"key":"2026012115084856000_ehf212555-bib-0001","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1002\/ehf2.12036","article-title":"Heart failure in Southeast Asia: facts and numbers","volume":"2","author":"Lam","year":"2015","journal-title":"ESC Heart Fail"},{"key":"2026012115084856000_ehf212555-bib-0002","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1002\/ejhf.1223","article-title":"Multi-ethnic comparisons of diabetes in heart failure with reduced ejection fraction: insights from the HF-ACTION trial and the ASIAN-HF registry","volume":"20","author":"Cooper","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"2026012115084856000_ehf212555-bib-0003","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1002\/ejhf.1210","article-title":"Validation of U.S. mortality prediction models for hospitalized heart failure in the United Kingdom and Japan","volume":"20","author":"Nagai","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"2026012115084856000_ehf212555-bib-0004","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1002\/ejhf.592","article-title":"2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC","volume":"18","author":"Ponikowski","year":"2016","journal-title":"Eur J Heart Fail"},{"key":"2026012115084856000_ehf212555-bib-0005","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1002\/ejhf.1234","article-title":"Incremental benefit of drug therapies for chronic heart failure with reduced ejection fraction: a network meta-analysis","volume":"20","author":"Komajda","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"2026012115084856000_ehf212555-bib-0006","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1002\/ejhf.1285","article-title":"Phenotypic profile of Ile68Leu transthyretin amyloidosis: an underdiagnosed cause of heart failure","volume":"20","author":"Gagliardi","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"2026012115084856000_ehf212555-bib-0007","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1002\/ejhf.1241","article-title":"The clinical outcome of LMNA missense mutations can be associated with the amount of mutated protein in the nuclear envelope","volume":"20","author":"Al-Saaidi","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"2026012115084856000_ehf212555-bib-0008","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1002\/ejhf.673","article-title":"Truncating titin mutations are associated with a mild and treatable form of dilated cardiomyopathy","volume":"19","author":"Jansweijer","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"2026012115084856000_ehf212555-bib-0009","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1002\/ejhf.699","article-title":"Brain natriuretic peptide usefulness in very elderly dyspnoeic patients: the BED study","volume":"19","author":"Plichart","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"2026012115084856000_ehf212555-bib-0010","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1002\/ejhf.1209","article-title":"Sex-specific associations of obesity and N-terminal pro-B-type natriuretic peptide levels in the general population","volume":"20","author":"Suthahar","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"2026012115084856000_ehf212555-bib-0011","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1002\/ehf2.12204","article-title":"Renin-angiotensin blockade in heart failure with preserved ejection fraction: a systematic review and meta-analysis","volume":"4","author":"Khan","year":"2017","journal-title":"ESC Heart Fail"},{"key":"2026012115084856000_ehf212555-bib-0012","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1002\/ejhf.822","article-title":"Do patients have worse outcomes in heart failure than in cancer? A primary care-based cohort study with 10-year follow-up in Scotland","volume":"19","author":"Mamas","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"2026012115084856000_ehf212555-bib-0013","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1161\/CIRCULATIONAHA.107.696906","article-title":"Candesartan in heart failure: assessment of reduction in M and morbidity I. Influence of nonfatal hospitalization for heart failure on subsequent mortality in patients with chronic heart failure","volume":"116","author":"Solomon","year":"2007","journal-title":"Circulation"},{"key":"2026012115084856000_ehf212555-bib-0014","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1002\/ejhf.566","article-title":"European Society of Cardiology Heart Failure Long-Term Registry (ESC-HF-LT): 1-year follow-up outcomes and differences across regions","volume":"18","author":"Crespo-Leiro","year":"2016","journal-title":"Eur J Heart Fail"},{"key":"2026012115084856000_ehf212555-bib-0015","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1002\/ejhf.890","article-title":"Clinical phenotypes and outcome of patients hospitalized for acute heart failure: the ESC Heart Failure Long-Term Registry","volume":"19","author":"Chioncel","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"2026012115084856000_ehf212555-bib-0016","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1002\/ejhf.515","article-title":"Worsening heart failure in \u2018real-world\u2019 clinical practice: predictors and prognostic impact","volume":"19","author":"AlFaleh","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"2026012115084856000_ehf212555-bib-0017","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1002\/ejhf.1236","article-title":"Advanced heart failure: a position statement of the Heart Failure Association of the European Society of Cardiology","volume":"20","author":"Crespo-Leiro","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"2026012115084856000_ehf212555-bib-0018","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1002\/ejhf.629","article-title":"Insufficient reduction in heart rate during hospitalization despite beta-blocker treatment in acute decompensated heart failure: insights from the ASCEND-HF trial","volume":"19","author":"Kitai","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"2026012115084856000_ehf212555-bib-0019","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1002\/ejhf.805","article-title":"Prognostic value of long-term blood pressure changes in patients with chronic heart failure","volume":"19","author":"Schmid","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"2026012115084856000_ehf212555-bib-0020","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1002\/ejhf.902","article-title":"Heart rate and its reduction in chronic heart failure and beyond","volume":"19","author":"Nikolovska Vukadinovic","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"2026012115084856000_ehf212555-bib-0021","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1002\/ejhf.988","article-title":"Prognostic importance of emerging cardiac, inflammatory, and renal biomarkers in chronic heart failure patients with reduced ejection fraction and anaemia: RED-HF study","volume":"20","author":"Welsh","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"2026012115084856000_ehf212555-bib-0022","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1002\/ejhf.1019","article-title":"Pre-discharge and early post-discharge troponin elevation among patients hospitalized for heart failure with reduced ejection fraction: findings from the ASTRONAUT trial","volume":"20","author":"Greene","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"2026012115084856000_ehf212555-bib-0023","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1002\/ejhf.766","article-title":"Plasma biomarkers to predict or rule out early post-discharge events after hospitalization for acute heart failure","volume":"19","author":"Demissei","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"2026012115084856000_ehf212555-bib-0024","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1002\/ejhf.749","article-title":"A multimarker multi-time point-based risk stratification strategy in acute heart failure: results from the RELAX-AHF trial","volume":"19","author":"Demissei","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"2026012115084856000_ehf212555-bib-0025","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1002\/ejhf.786","article-title":"Measurement of troponin and natriuretic peptides shortly after admission in patients with heart failure-does it add useful prognostic information? An analysis of the Value of Endothelin Receptor Inhibition with Tezosentan in Acute heart failure Studies (VERITAS)","volume":"19","author":"Cleland","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"2026012115084856000_ehf212555-bib-0026","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1002\/ejhf.973","article-title":"Plasma renin activity, response to aliskiren, and clinical outcomes in patients hospitalized for heart failure: the ASTRONAUT trial","volume":"20","author":"Vaduganathan","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"2026012115084856000_ehf212555-bib-0027","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1002\/ejhf.1301","article-title":"Growth differentiation factor-15 is not modified by sacubitril\/valsartan and is an independent marker of risk in patients with heart failure and reduced ejection fraction: the PARADIGM-HF trial","volume":"20","author":"Bouabdallaoui","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"2026012115084856000_ehf212555-bib-0028","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1002\/ejhf.1119","article-title":"Transcoronary concentration gradients of circulating microRNAs in heart failure","volume":"20","author":"De Rosa","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"2026012115084856000_ehf212555-bib-0029","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1002\/ejhf.495","article-title":"MicroRNAs in heart failure: from biomarker to target for therapy","volume":"18","author":"Vegter","year":"2016","journal-title":"Eur J Heart Fail"},{"key":"2026012115084856000_ehf212555-bib-0030","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1002\/ejhf.950","article-title":"Serially measured circulating microRNAs and adverse clinical outcomes in patients with acute heart failure","volume":"20","author":"van Boven","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"2026012115084856000_ehf212555-bib-0031","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1002\/ejhf.984","article-title":"Prognostic value of circulating microRNAs on heart failure-related morbidity and mortality in two large diverse cohorts of general heart failure patients","volume":"20","author":"Bayes-Genis","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"2026012115084856000_ehf212555-bib-0032","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1002\/ejhf.989","article-title":"Multiparametric prognostic scores in chronic heart failure with reduced ejection fraction: a long-term comparison","volume":"20","author":"Agostoni","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"2026012115084856000_ehf212555-bib-0033","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1002\/ejhf.785","article-title":"Development and validation of multivariable models to predict mortality and hospitalization in patients with heart failure","volume":"19","author":"Voors","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"2026012115084856000_ehf212555-bib-0034","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1002\/ejhf.971","article-title":"Non-invasive assessment of left ventricular filling pressure","volume":"20","author":"Nagueh","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"2026012115084856000_ehf212555-bib-0035","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1002\/ejhf.957","article-title":"Echocardiographic estimation of left ventricular and pulmonary pressures in patients with heart failure and preserved ejection fraction: a study utilizing simultaneous echocardiography and invasive measurements","volume":"19","author":"Hummel","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"2026012115084856000_ehf212555-bib-0036","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1002\/ejhf.664","article-title":"Different correlates but similar prognostic implications for right ventricular dysfunction in heart failure patients with reduced or preserved ejection fraction","volume":"19","author":"Ghio","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"2026012115084856000_ehf212555-bib-0037","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1002\/ejhf.630","article-title":"Right ventricular dysfunction in heart failure with preserved ejection fraction: a systematic review and meta-analysis","volume":"18","author":"Gorter","year":"2016","journal-title":"Eur J Heart Fail"},{"key":"2026012115084856000_ehf212555-bib-0038","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1002\/ejhf.860","article-title":"Pulmonary hypertension due to left heart disease: analysis of survival according to the haemodynamic classification of the 2015 ESC\/ERS guidelines and insights for future changes","volume":"20","author":"Palazzini","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"2026012115084856000_ehf212555-bib-0039","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1002\/ejhf.675","article-title":"Determinants and prognostic implications of the negative diastolic pulmonary pressure gradient in patients with pulmonary hypertension due to left heart disease","volume":"19","author":"Nagy","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"2026012115084856000_ehf212555-bib-0040","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin-neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N Engl J Med"},{"key":"2026012115084856000_ehf212555-bib-0041","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1002\/ejhf.1139","article-title":"Effect of sacubitril\/valsartan on recurrent events in the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF)","volume":"20","author":"Mogensen","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"2026012115084856000_ehf212555-bib-0042","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1001\/jamacardio.2018.0398","article-title":"Effects of sacubitril\/valsartan on physical and social activity limitations in patients with heart failure: a secondary analysis of the PARADIGM-HF Trial","volume":"3","author":"Chandra","year":"2018","journal-title":"JAMA Cardiol"},{"key":"2026012115084856000_ehf212555-bib-0043","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1002\/ejhf.1402","article-title":"Reduced loop diuretic use in patients taking sacubitril\/valsartan compared with enalapril: the PARADIGM-HF trial","volume":"21","author":"Vardeny","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"2026012115084856000_ehf212555-bib-0044","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1056\/NEJMoa1812851","article-title":"Angiotensin-neprilysin inhibition in acute decompensated heart failure","volume":"380","author":"Velazquez","year":"2019","journal-title":"N Engl J Med"},{"key":"2026012115084856000_ehf212555-bib-0045","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1002\/ejhf.1531","article-title":"Clinical practice update on heart failure 2019: pharmacotherapy, procedures, devices and patient management. An expert consensus meeting report of the Heart Failure Association of the European Society of Cardiology","volume":"21","author":"Seferovic","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"2026012115084856000_ehf212555-bib-0046","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1002\/ejhf.1498","article-title":"Initiation of sacubitril\/valsartan in haemodynamically stabilised heart failure patients in hospital or early after discharge: primary results of the randomised TRANSITION study","volume":"21","author":"Wachter","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"2026012115084856000_ehf212555-bib-0047","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1002\/ejhf.887","article-title":"Physicians' guideline adherence is associated with better prognosis in outpatients with heart failure with reduced ejection fraction: the QUALIFY international registry","volume":"19","author":"Komajda","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"2026012115084856000_ehf212555-bib-0048","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1002\/ehf2.12205","article-title":"Clinical practices and attitudes regarding the diagnosis and management of heart failure: findings from the CORE Needs Assessment Survey","volume":"5","author":"Howlett","year":"2018","journal-title":"ESC Heart Fail"},{"key":"2026012115084856000_ehf212555-bib-0049","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1002\/ejhf.1159","article-title":"The role of angiotensin receptor-neprilysin inhibitors in cardiovascular disease-existing evidence, knowledge gaps, and future directions","volume":"20","author":"Ambrosy","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"2026012115084856000_ehf212555-bib-0050","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1002\/ejhf.788","article-title":"What proportion of patients with chronic heart failure are eligible for sacubitril-valsartan?","volume":"19","author":"Pellicori","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"2026012115084856000_ehf212555-bib-0051","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1002\/ejhf.1054","article-title":"Impact of systolic blood pressure on the safety and tolerability of initiating and up-titrating sacubitril\/valsartan in patients with heart failure and reduced ejection fraction: insights from the TITRATION study","volume":"20","author":"Senni","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"2026012115084856000_ehf212555-bib-0052","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1002\/ejhf.1217","article-title":"Need to revisit heart failure treatment guidelines for hyperkalaemia management during the use of mineralocorticoid receptor antagonists","volume":"20","author":"Butler","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"2026012115084856000_ehf212555-bib-0053","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1002\/ejhf.814","article-title":"Tailoring mineralocorticoid receptor antagonist therapy in heart failure patients: are we moving towards a personalized approach?","volume":"19","author":"Ferreira","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"2026012115084856000_ehf212555-bib-0054","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1002\/ejhf.900","article-title":"Mineralocorticoid receptor antagonist pattern of use in heart failure with reduced ejection fraction: findings from BIOSTAT-CHF","volume":"19","author":"Ferreira","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"2026012115084856000_ehf212555-bib-0055","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1002\/ejhf.1079","article-title":"Potassium and the use of renin-angiotensin-aldosterone system inhibitors in heart failure with reduced ejection fraction: data from BIOSTAT-CHF","volume":"20","author":"Beusekamp","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"2026012115084856000_ehf212555-bib-0056","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1002\/ejhf.1199","article-title":"Incidence, predictors and clinical management of hyperkalaemia in new users of mineralocorticoid receptor antagonists","volume":"20","author":"Trevisan","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"2026012115084856000_ehf212555-bib-0057","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1002\/ejhf.1182","article-title":"Factors associated with underuse of mineralocorticoid receptor antagonists in heart failure with reduced ejection fraction: an analysis of 11 215 patients from the Swedish Heart Failure Registry","volume":"20","author":"Savarese","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"2026012115084856000_ehf212555-bib-0058","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1002\/ejhf.640","article-title":"Myocardial iron content and mitochondrial function in human heart failure: a direct tissue analysis","volume":"19","author":"Melenovsky","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"2026012115084856000_ehf212555-bib-0059","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1002\/ejhf.938","article-title":"Limited contractile reserve contributes to poor peak exercise capacity in iron-deficient heart failure","volume":"20","author":"Martens","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"2026012115084856000_ehf212555-bib-0060","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1002\/ejhf.1154","article-title":"Iron deficiency impairs contractility of human cardiomyocytes through decreased mitochondrial function","volume":"20","author":"Hoes","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"2026012115084856000_ehf212555-bib-0061","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1002\/ejhf.1305","article-title":"Screening, diagnosis and treatment of iron deficiency in chronic heart failure: putting the 2016 European Society of Cardiology heart failure guidelines into clinical practice","volume":"20","author":"McDonagh","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"2026012115084856000_ehf212555-bib-0062","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.jchf.2018.07.015","article-title":"Iron deficiency in heart failure: an overview","volume":"7","author":"von Haehling","year":"2019","journal-title":"JACC Heart Fail"},{"key":"2026012115084856000_ehf212555-bib-0063","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1002\/ejhf.823","article-title":"Effects of ferric carboxymaltose on hospitalisations and mortality rates in iron-deficient heart failure patients: an individual patient data meta-analysis","volume":"20","author":"Anker","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"2026012115084856000_ehf212555-bib-0064","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1002\/ejhf.633","article-title":"Heart failure outcomes in clinical trials of glucose-lowering agents in patients with diabetes","volume":"19","author":"Fitchett","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"2026012115084856000_ehf212555-bib-0065","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1002\/ejhf.1170","article-title":"Type 2 diabetes mellitus and heart failure: a position statement from the Heart Failure Association of the European Society of Cardiology","volume":"20","author":"Seferovic","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"2026012115084856000_ehf212555-bib-0066","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1056\/NEJMoa072761","article-title":"Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes","volume":"356","author":"Nissen","year":"2007","journal-title":"N Engl J Med"},{"key":"2026012115084856000_ehf212555-bib-0067","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1002\/ejhf.1146","article-title":"Treatment with insulin is associated with worse outcome in patients with chronic heart failure and diabetes","volume":"20","author":"Cosmi","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"2026012115084856000_ehf212555-bib-0068","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1056\/NEJMoa1307684","article-title":"Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus","volume":"369","author":"Scirica","year":"2013","journal-title":"N Engl J Med"},{"key":"2026012115084856000_ehf212555-bib-0069","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"2026012115084856000_ehf212555-bib-0070","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1002\/ejhf.657","article-title":"Effect of liraglutide, a glucagon-like peptide-1 analogue, on left ventricular function in stable chronic heart failure patients with and without diabetes (LIVE)-a multicentre, double-blind, randomised, placebo-controlled trial","volume":"19","author":"Jorsal","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"2026012115084856000_ehf212555-bib-0071","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1002\/ejhf.933","article-title":"The potential role and rationale for treatment of heart failure with sodium-glucose co-transporter 2 inhibitors","volume":"19","author":"Butler","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"2026012115084856000_ehf212555-bib-0072","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"key":"2026012115084856000_ehf212555-bib-0073","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N Engl J Med"},{"key":"2026012115084856000_ehf212555-bib-0074","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"N Engl J Med"},{"key":"2026012115084856000_ehf212555-bib-0075","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1002\/ejhf.1328","article-title":"Empagliflozin directly improves diastolic function in human heart failure","volume":"20","author":"Pabel","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"2026012115084856000_ehf212555-bib-0076","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1161\/CIRCULATIONAHA.117.030012","article-title":"Sodium glucose cotransporter-2 inhibition in heart failure: potential mechanisms, clinical applications, and summary of clinical trials","volume":"136","author":"Lytvyn","year":"2017","journal-title":"Circulation"},{"key":"2026012115084856000_ehf212555-bib-0077","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1007\/s00125-018-4670-7","article-title":"SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review","volume":"61","author":"Verma","year":"2018","journal-title":"Diabetologia"},{"key":"2026012115084856000_ehf212555-bib-0078","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1002\/ejhf.1432","article-title":"A trial to evaluate the effect of the sodium-glucose co-transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA-HF)","volume":"21","author":"McMurray","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"2026012115084856000_ehf212555-bib-0079","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N Engl J Med"},{"key":"2026012115084856000_ehf212555-bib-0080","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.jchf.2018.03.019","article-title":"Ambulatory inotrope infusions in advanced heart failure: a systematic review and meta-analysis","volume":"6","author":"Nizamic","year":"2018","journal-title":"JACC Heart Fail"},{"key":"2026012115084856000_ehf212555-bib-0081","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1002\/ehf2.12114","article-title":"Quality of life and long-term mortality in patients with advanced chronic heart failure treated with intermittent low-dose intravenous inotropes in an outpatient setting","volume":"4","author":"Chernomordik","year":"2017","journal-title":"ESC Heart Fail"},{"key":"2026012115084856000_ehf212555-bib-0082","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1002\/ehf2.12177","article-title":"Rehospitalization after intermittent levosimendan treatment in advanced heart failure patients: a meta-analysis of randomized trials","volume":"4","author":"Silvetti","year":"2017","journal-title":"ESC Heart Fail"},{"key":"2026012115084856000_ehf212555-bib-0083","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1002\/ejhf.1145","article-title":"Efficacy and safety of intermittent intravenous outpatient administration of levosimendan in patients with advanced heart failure: the LION-HEART multicentre randomised trial","volume":"20","author":"Comin-Colet","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"2026012115084856000_ehf212555-bib-0084","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1002\/ejhf.1158","article-title":"Direct comparison of ultrafiltration to pharmacological decongestion in heart failure: a per-protocol analysis of CARRESS-HF","volume":"20","author":"Grodin","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"2026012115084856000_ehf212555-bib-0085","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.cardfail.2011.12.009","article-title":"Cardiorenal rescue study in acute decompensated heart failure: rationale and design of CARRESS-HF, for the Heart Failure Clinical Research Network","volume":"18","author":"Bart","year":"2012","journal-title":"J Card Fail"},{"key":"2026012115084856000_ehf212555-bib-0086","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1002\/ejhf.1240","article-title":"Which patients with heart failure should receive specialist palliative care?","volume":"20","author":"Campbell","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"2026012115084856000_ehf212555-bib-0087","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1002\/ehf2.12125","article-title":"Palliative care in heart failure: facts and numbers","volume":"4","author":"Riley","year":"2017","journal-title":"ESC Heart Fail"},{"key":"2026012115084856000_ehf212555-bib-0088","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1002\/ejhf.929","article-title":"Effect of expanding evidence and evolving clinical guidelines on the prevalence of indication for cardiac resynchronization therapy in patients with heart failure","volume":"20","author":"Lund","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"2026012115084856000_ehf212555-bib-0089","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1002\/ejhf.1142","article-title":"CRT Survey II: a European Society of Cardiology survey of cardiac resynchronisation therapy in 11 088 patients-who is doing what to whom and how?","volume":"20","author":"Dickstein","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"2026012115084856000_ehf212555-bib-0090","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1002\/ejhf.781","article-title":"Association between demographic, organizational, clinical, and socio-economic characteristics and underutilization of cardiac resynchronization therapy: results from the Swedish Heart Failure Registry","volume":"19","author":"Lund","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"2026012115084856000_ehf212555-bib-0091","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1002\/ejhf.795","article-title":"Predictors of short-term clinical response to cardiac resynchronization therapy","volume":"19","author":"Linde","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"2026012115084856000_ehf212555-bib-0092","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1002\/ejhf.769","article-title":"Impact of QRS complex duration and morphology on left ventricular reverse remodelling and left ventricular function improvement after cardiac resynchronization therapy","volume":"19","author":"van der Bijl","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"2026012115084856000_ehf212555-bib-0093","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1002\/ehf2.12122","article-title":"QRS duration versus morphology and survival after cardiac resynchronization therapy","volume":"4","author":"Khidir","year":"2017","journal-title":"ESC Heart Fail"},{"key":"2026012115084856000_ehf212555-bib-0094","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1002\/ejhf.1133","article-title":"The interaction of sex, height, and QRS duration on the effects of cardiac resynchronization therapy on morbidity and mortality: an individual-patient data meta-analysis","volume":"20","author":"Linde","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"2026012115084856000_ehf212555-bib-0095","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1002\/ejhf.1235","article-title":"Upgrades from a previous device compared to de novo cardiac resynchronization therapy in the European Society of Cardiology CRT Survey II","volume":"20","author":"Linde","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"2026012115084856000_ehf212555-bib-0096","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1002\/ejhf.1117","article-title":"Atrioventricular junction ablation in patients with atrial fibrillation treated with cardiac resynchronization therapy: positive impact on ventricular arrhythmias, implantable cardioverter-defibrillator therapies and hospitalizations","volume":"20","author":"Gasparini","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"2026012115084856000_ehf212555-bib-0097","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1002\/ejhf.906","article-title":"Left ventricular-only pacing in heart failure patients with normal atrioventricular conduction improves global function and left ventricular regional mechanics compared with biventricular pacing: an adaptive cardiac resynchronization therapy sub-study","volume":"19","author":"Burns","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"2026012115084856000_ehf212555-bib-0098","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1002\/ejhf.895","article-title":"Rationale and design of the AdaptResponse trial: a prospective randomized study of cardiac resynchronization therapy with preferential adaptive left ventricular-only pacing","volume":"19","author":"Filippatos","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"2026012115084856000_ehf212555-bib-0099","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1056\/NEJMoa1608029","article-title":"Defibrillator implantation in patients with nonischemic systolic heart failure","volume":"375","author":"Kober","year":"2016","journal-title":"N Engl J Med"},{"key":"2026012115084856000_ehf212555-bib-0100","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1002\/ejhf.1192","article-title":"Implantable cardioverter-defibrillators in heart failure patients with reduced ejection fraction and diabetes","volume":"20","author":"Sharma","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"2026012115084856000_ehf212555-bib-0101","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1002\/ejhf.685","article-title":"The impact of co-morbidity burden on appropriate implantable cardioverter defibrillator therapy and all-cause mortality: insight from Danish nationwide clinical registers","volume":"19","author":"Ruwald","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"2026012115084856000_ehf212555-bib-0102","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1002\/ejhf.743","article-title":"Patient outcome after implant of a cardioverter defibrillator in the \u2018real world\u2019: the key role of co-morbidities","volume":"19","author":"Boriani","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"2026012115084856000_ehf212555-bib-0103","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1002\/ejhf.765","article-title":"Comparative effectiveness of transitional care services in patients discharged from the hospital with heart failure: a systematic review and network meta-analysis","volume":"19","author":"Van Spall","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"2026012115084856000_ehf212555-bib-0104","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1002\/ejhf.1053","article-title":"Daily home BNP monitoring in heart failure for prediction of impending clinical deterioration: results from the HOME HF study","volume":"20","author":"McDonald","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"2026012115084856000_ehf212555-bib-0105","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1002\/ejhf.1300","article-title":"Telemedical Interventional Management in Heart Failure II (TIM-HF2), a randomised, controlled trial investigating the impact of telemedicine on unplanned cardiovascular hospitalisations and mortality in heart failure patients: study design and description of the intervention","volume":"20","author":"Koehler","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"2026012115084856000_ehf212555-bib-0106","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1056\/NEJMoa1806640","article-title":"Transcatheter mitral-valve repair in patients with heart failure","volume":"379","author":"Stone","year":"2018","journal-title":"N Engl J Med"},{"key":"2026012115084856000_ehf212555-bib-0107","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1056\/NEJMoa1805374","article-title":"Percutaneous repair or medical treatment for secondary mitral regurgitation","volume":"379","author":"Obadia","year":"2018","journal-title":"N Engl J Med"},{"key":"2026012115084856000_ehf212555-bib-0108","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1002\/ejhf.1491","article-title":"Treatment of functional mitral regurgitation in chronic heart failure: can we get a \u2018proof of concept\u2019 from the MITRA-FR and COAPT trials?","volume":"21","author":"Senni","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"2026012115084856000_ehf212555-bib-0109","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1002\/ejhf.864","article-title":"Implication of pulmonary hypertension in patients undergoing MitraClip therapy: results from the German transcatheter mitral valve interventions (TRAMI) registry","volume":"20","author":"Tigges","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"2026012115084856000_ehf212555-bib-0110","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1002\/ejhf.910","article-title":"Safety and efficacy of MitraClip therapy in patients with severely impaired left ventricular ejection fraction: results from the German transcatheter mitral valve interventions (TRAMI) registry","volume":"20","author":"Geis","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"2026012115084856000_ehf212555-bib-0111","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1002\/ejhf.1147","article-title":"Six-month outcome after transcatheter edge-to-edge repair of severe tricuspid regurgitation in patients with heart failure","volume":"20","author":"Orban","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"2026012115084856000_ehf212555-bib-0112","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1002\/ejhf.975","article-title":"Screening for heart transplantation and left ventricular assist system: results from the ScrEEning for advanced Heart Failure treatment (SEE-HF) study","volume":"20","author":"Lund","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"2026012115084856000_ehf212555-bib-0113","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1002\/ejhf.779","article-title":"Left ventricular assist device therapy in advanced heart failure: patient selection and outcomes","volume":"19","author":"Gustafsson","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"2026012115084856000_ehf212555-bib-0114","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1002\/ejhf.956","article-title":"Clinical outcomes of temporary mechanical circulatory support as a direct bridge to heart transplantation: a nationwide Spanish registry","volume":"20","author":"Barge-Caballero","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"2026012115084856000_ehf212555-bib-0115","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1002\/ejhf.1018","article-title":"Clinical and histopathological effects of heart failure drug therapy in advanced heart failure patients on chronic mechanical circulatory support","volume":"20","author":"Catino","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"2026012115084856000_ehf212555-bib-0116","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1002\/ejhf.1113","article-title":"Platelet activation is a preoperative risk factor for the development of thromboembolic complications in patients with continuous-flow left ventricular assist device","volume":"20","author":"Consolo","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"2026012115084856000_ehf212555-bib-0117","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1056\/NEJMoa1900486","article-title":"A fully magnetically levitated left ventricular assist device\u2014Final report","volume":"380","author":"Mehra","year":"2019","journal-title":"N Engl J Med"},{"key":"2026012115084856000_ehf212555-bib-0118","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1002\/ejhf.921","article-title":"The autonomic nervous system as a therapeutic target in heart failure: a scientific position statement from the Translational Research Committee of the Heart Failure Association of the European Society of Cardiology","volume":"19","author":"van Bilsen","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"2026012115084856000_ehf212555-bib-0119","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1002\/ejhf.641","article-title":"Carotid body resection for sympathetic modulation in systolic heart failure: results from first-in-man study","volume":"19","author":"Niewinski","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"2026012115084856000_ehf212555-bib-0120","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1056\/NEJMoa1506459","article-title":"Adaptive servo-ventilation for central sleep apnea in systolic heart failure","volume":"373","author":"Cowie","year":"2015","journal-title":"N Engl J Med"},{"key":"2026012115084856000_ehf212555-bib-0121","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1002\/ejhf.1048","article-title":"Adaptive servo-ventilation for central sleep apnoea in systolic heart failure: results of the major substudy of SERVE-HF","volume":"20","author":"Cowie","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"2026012115084856000_ehf212555-bib-0122","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1002\/ejhf.790","article-title":"Design of the effect of adaptive servo-ventilation on survival and cardiovascular hospital admissions in patients with heart failure and sleep apnoea: the ADVENT-HF trial","volume":"19","author":"Lyons","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"2026012115084856000_ehf212555-bib-0123","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1002\/ejhf.1312","article-title":"Phrenic nerve stimulation to treat patients with central sleep apnoea and heart failure","volume":"20","author":"Costanzo","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"2026012115084856000_ehf212555-bib-0124","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1002\/ejhf.700","article-title":"Safety, feasibility and effectiveness of first in-human administration of muscle-derived stem\/progenitor cells modified with connexin-43 gene for treatment of advanced chronic heart failure","volume":"19","author":"Gwizdala","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"2026012115084856000_ehf212555-bib-0125","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1002\/ejhf.676","article-title":"An exploratory randomized control study of combination cytokine and adult autologous bone marrow progenitor cell administration in patients with ischaemic cardiomyopathy: the REGENERATE-IHD clinical trial","volume":"19","author":"Choudhury","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"2026012115084856000_ehf212555-bib-0126","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1002\/ejhf.898","article-title":"Benefit of cardiopoietic mesenchymal stem cell therapy on left ventricular remodelling: results from the Congestive Heart Failure Cardiopoietic Regenerative Therapy (CHART-1) study","volume":"19","author":"Teerlink","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"2026012115084856000_ehf212555-bib-0127","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1002\/ehf2.12200","article-title":"A prospective evaluation of the established criteria for heart failure with preserved ejection fraction using the Alberta HEART cohort","volume":"5","author":"Ezekowitz","year":"2018","journal-title":"ESC Heart Fail"},{"key":"2026012115084856000_ehf212555-bib-0128","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1161\/CIRCULATIONAHA.116.024822","article-title":"Role of diastolic stress testing in the evaluation for heart failure with preserved ejection fraction: a simultaneous invasive-echocardiographic study","volume":"135","author":"Obokata","year":"2017","journal-title":"Circulation"},{"key":"2026012115084856000_ehf212555-bib-0129","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1161\/CIRCULATIONAHA.117.029058","article-title":"Exercise intolerance in heart failure with preserved ejection fraction: diagnosing and ranking its causes using personalized O2 pathway analysis","volume":"137","author":"Houstis","year":"2018","journal-title":"Circulation"},{"key":"2026012115084856000_ehf212555-bib-0130","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1002\/ehf2.12281","article-title":"Heart rate response and functional capacity in patients with chronic heart failure with preserved ejection fraction","volume":"5","author":"Dominguez","year":"2018","journal-title":"ESC Heart Fail"},{"key":"2026012115084856000_ehf212555-bib-0131","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1002\/ejhf.913","article-title":"Physiological dead space and arterial carbon dioxide contributions to exercise ventilatory inefficiency in patients with reduced or preserved ejection fraction heart failure","volume":"19","author":"Van Iterson","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"2026012115084856000_ehf212555-bib-0132","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1002\/ejhf.1073","article-title":"Contribution of cardiac and extra-cardiac disease burden to risk of cardiovascular outcomes varies by ejection fraction in heart failure","volume":"20","author":"Wolsk","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"2026012115084856000_ehf212555-bib-0133","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1002\/ejhf.1077","article-title":"Prevalence of left ventricular systolic dysfunction in pre-dialysis and dialysis patients with preserved left ventricular ejection fraction","volume":"20","author":"Hensen","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"2026012115084856000_ehf212555-bib-0134","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1002\/ejhf.821","article-title":"Associations with and prognostic impact of chronic kidney disease in heart failure with preserved, mid-range, and reduced ejection fraction","volume":"19","author":"Lofman","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"2026012115084856000_ehf212555-bib-0135","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1002\/ejhf.976","article-title":"Resting and exercise haemodynamics in relation to six-minute walk test in patients with heart failure and preserved ejection fraction","volume":"20","author":"Wolsk","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"2026012115084856000_ehf212555-bib-0136","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/ejhf.979","article-title":"Role of cardiopulmonary exercise testing in clinical stratification in heart failure. A position paper from the Committee on Exercise Physiology and Training of the Heart Failure Association of the European Society of Cardiology","volume":"20","author":"Corra","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"2026012115084856000_ehf212555-bib-0137","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1002\/ejhf.930","article-title":"Impact of atrial fibrillation on rest and exercise haemodynamics in heart failure with mid-range and preserved ejection fraction","volume":"19","author":"Kaye","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"2026012115084856000_ehf212555-bib-0138","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1002\/ehf2.12225","article-title":"Exercise and heart failure: an update","volume":"5","author":"Cattadori","year":"2018","journal-title":"ESC Heart Fail"},{"key":"2026012115084856000_ehf212555-bib-0139","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1002\/ejhf.1140","article-title":"A flattening oxygen consumption trajectory phenotypes disease severity and poor prognosis in patients with heart failure with reduced, mid-range, and preserved ejection fraction","volume":"20","author":"Popovic","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"2026012115084856000_ehf212555-bib-0140","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1002\/ejhf.694","article-title":"Myocardial strain to detect subtle left ventricular systolic dysfunction","volume":"19","author":"Tops","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"2026012115084856000_ehf212555-bib-0141","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1002\/ejhf.754","article-title":"Impaired left ventricular global longitudinal strain in patients with heart failure with preserved ejection fraction: insights from the RELAX trial","volume":"19","author":"DeVore","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"2026012115084856000_ehf212555-bib-0142","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1002\/ehf2.12159","article-title":"Left ventricular global longitudinal strain in patients with heart failure with preserved ejection fraction: outcomes following an acute heart failure hospitalization","volume":"4","author":"Buggey","year":"2017","journal-title":"ESC Heart Fail"},{"key":"2026012115084856000_ehf212555-bib-0143","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1161\/CIRCULATIONAHA.116.026807","article-title":"Evidence supporting the existence of a distinct obese phenotype of heart failure with preserved ejection fraction","volume":"136","author":"Obokata","year":"2017","journal-title":"Circulation"},{"key":"2026012115084856000_ehf212555-bib-0144","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1016\/j.jchf.2018.06.002","article-title":"Regional adipose distribution and its relationship to exercise intolerance in older obese patients who have heart failure with preserved ejection fraction","volume":"6","author":"Haykowsky","year":"2018","journal-title":"JACC Heart Fail"},{"key":"2026012115084856000_ehf212555-bib-0145","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1002\/ejhf.1283","article-title":"Epicardial fat in heart failure patients with mid-range and preserved ejection fraction","volume":"20","author":"van Woerden","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"2026012115084856000_ehf212555-bib-0146","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1002\/ejhf.792","article-title":"Effect of eplerenone in patients with heart failure and reduced ejection fraction: potential effect modification by abdominal obesity. Insight from the EMPHASIS-HF trial","volume":"19","author":"Olivier","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"2026012115084856000_ehf212555-bib-0147","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1002\/ejhf.1167","article-title":"Derangements in adrenergic-adipokine signalling establish a neurohormonal basis for obesity-related heart failure with a preserved ejection fraction","volume":"20","author":"Packer","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"2026012115084856000_ehf212555-bib-0148","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1002\/ejhf.1185","article-title":"Augmentation of glucagon-like peptide-1 receptor signalling by neprilysin inhibition: potential implications for patients with heart failure","volume":"20","author":"Packer","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"2026012115084856000_ehf212555-bib-0149","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1002\/ejhf.1194","article-title":"Biomarker-based phenotyping of myocardial fibrosis identifies patients with heart failure with preserved ejection fraction resistant to the beneficial effects of spironolactone: results from the Aldo-DHF trial","volume":"20","author":"Ravassa","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"2026012115084856000_ehf212555-bib-0150","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1002\/ehf2.12239","article-title":"Outcomes following heart failure hospitalization in a regional Australian setting between 2005 and 2014","volume":"5","author":"Al-Omary","year":"2018","journal-title":"ESC Heart Fail"},{"key":"2026012115084856000_ehf212555-bib-0151","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1002\/ejhf.960","article-title":"Investigating a biomarker-driven approach to target collagen turnover in diabetic heart failure with preserved ejection fraction patients. Effect of torasemide versus furosemide on serum C-terminal propeptide of procollagen type I (DROP-PIP trial)","volume":"20","author":"Trippel","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"2026012115084856000_ehf212555-bib-0152","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1002\/ehf2.12218","article-title":"Rationale of the FIBROTARGETS study designed to identify novel biomarkers of myocardial fibrosis","volume":"5","author":"Ferreira","year":"2018","journal-title":"ESC Heart Fail"},{"key":"2026012115084856000_ehf212555-bib-0153","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1161\/CIRCULATIONAHA.114.013255","article-title":"Regional variation in patients and outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) trial","volume":"131","author":"Pfeffer","year":"2015","journal-title":"Circulation"},{"key":"2026012115084856000_ehf212555-bib-0154","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.jacbts.2016.03.001","article-title":"Detection and management of geographic disparities in the TOPCAT trial: lessons learned and derivative recommendations","volume":"1","author":"Bristow","year":"2016","journal-title":"JACC Basic Transl Sci"},{"key":"2026012115084856000_ehf212555-bib-0155","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1002\/ejhf.686","article-title":"Data and safety monitoring board evaluation and management of a renal adverse event signal in TOPCAT","volume":"19","author":"Bristow","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"2026012115084856000_ehf212555-bib-0156","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1093\/eurheartj\/ehv464","article-title":"Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart failure with preserved ejection fraction","volume":"37","author":"Solomon","year":"2016","journal-title":"Eur Heart J"},{"key":"2026012115084856000_ehf212555-bib-0157","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1002\/ejhf.1060","article-title":"Systolic blood pressure and cardiovascular outcomes in heart failure with preserved ejection fraction: an analysis of the TOPCAT trial","volume":"20","author":"Selvaraj","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"2026012115084856000_ehf212555-bib-0158","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1056\/NEJMoa1908655","article-title":"Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction","volume":"381","author":"Solomon","year":"2019","journal-title":"N Engl J Med"},{"key":"2026012115084856000_ehf212555-bib-0159","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1002\/ejhf.876","article-title":"Effect of ivabradine in patients with heart failure with preserved ejection fraction: the EDIFY randomized placebo-controlled trial","volume":"19","author":"Komajda","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"2026012115084856000_ehf212555-bib-0160","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1002\/ejhf.662","article-title":"Effects of sildenafil on cardiac structure and function, cardiopulmonary exercise testing and health-related quality of life measures in heart failure patients with preserved ejection fraction and pulmonary hypertension","volume":"19","author":"Liu","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"2026012115084856000_ehf212555-bib-0161","doi-asserted-by":"crossref","first-page":"2565","DOI":"10.1093\/eurheartj\/ehv336","article-title":"Effects of sildenafil on invasive haemodynamics and exercise capacity in heart failure patients with preserved ejection fraction and pulmonary hypertension: a randomized controlled trial","volume":"36","author":"Hoendermis","year":"2015","journal-title":"Eur Heart J"},{"key":"2026012115084856000_ehf212555-bib-0162","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1002\/ejhf.800","article-title":"Patient-reported outcomes in the SOluble guanylate Cyclase stimulatoR in heArT failurE patientS with PRESERVED ejection fraction (SOCRATES-PRESERVED) study","volume":"19","author":"Filippatos","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"2026012115084856000_ehf212555-bib-0163","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1093\/eurheartj\/ehw593","article-title":"Vericiguat in patients with worsening chronic heart failure and preserved ejection fraction: results of the SOluble guanylate Cyclase stimulatoR in heArT failurE patientS with PRESERVED EF (SOCRATES-PRESERVED) study","volume":"38","author":"Pieske","year":"2017","journal-title":"Eur Heart J"},{"key":"2026012115084856000_ehf212555-bib-0164","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.jchf.2017.08.013","article-title":"A multicenter, randomized, double-blind, placebo-controlled trial of the efficacy and safety of the oral soluble guanylate cyclase stimulator: the VICTORIA trial","volume":"6","author":"Armstrong","year":"2018","journal-title":"JACC Heart Fail"},{"key":"2026012115084856000_ehf212555-bib-0165","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1111\/jgs.14867","article-title":"Response to endurance exercise training in older adults with heart failure with preserved or reduced ejection fraction","volume":"65","author":"Pandey","year":"2017","journal-title":"J Am Geriatr Soc"},{"key":"2026012115084856000_ehf212555-bib-0166","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1161\/CIRCHEARTFAILURE.114.001615","article-title":"Exercise training in patients with heart failure and preserved ejection fraction: meta-analysis of randomized control trials","volume":"8","author":"Pandey","year":"2015","journal-title":"Circ Heart Fail"},{"key":"2026012115084856000_ehf212555-bib-0167","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1002\/ehf2.12227","article-title":"Amount or intensity? Potential targets of exercise interventions in patients with heart failure with preserved ejection fraction","volume":"5","author":"Bobenko","year":"2018","journal-title":"ESC Heart Fail"},{"key":"2026012115084856000_ehf212555-bib-0168","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1002\/ehf2.12149","article-title":"The effect of exercise training on biventricular myocardial strain in heart failure with preserved ejection fraction","volume":"4","author":"Angadi","year":"2017","journal-title":"ESC Heart Fail"},{"key":"2026012115084856000_ehf212555-bib-0169","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1001\/jama.2015.17346","article-title":"Effect of caloric restriction or aerobic exercise training on peak oxygen consumption and quality of life in obese older patients with heart failure with preserved ejection fraction: a randomized clinical trial","volume":"315","author":"Kitzman","year":"2016","journal-title":"JAMA"},{"key":"2026012115084856000_ehf212555-bib-0170","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1002\/ejhf.945","article-title":"A comprehensive population-based characterization of heart failure with mid-range ejection fraction","volume":"19","author":"Koh","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"2026012115084856000_ehf212555-bib-0171","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1002\/ejhf.879","article-title":"Epidemiology, pathophysiology and clinical outcomes for heart failure patients with a mid-range ejection fraction","volume":"19","author":"Rastogi","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"2026012115084856000_ehf212555-bib-0172","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1002\/ejhf.798","article-title":"Heart failure with mid-range ejection fraction: a distinct clinical entity? Insights from the Trial of Intensified versus standard Medical therapy in Elderly patients with Congestive Heart Failure (TIME-CHF)","volume":"19","author":"Rickenbacher","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"2026012115084856000_ehf212555-bib-0173","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1002\/ejhf.807","article-title":"Shimokawa H and Investigators C-. Characterization of heart failure patients with mid-range left ventricular ejection fraction-a report from the CHART-2 Study","volume":"19","author":"Tsuji","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"2026012115084856000_ehf212555-bib-0174","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.117.003875","article-title":"Significance of ischemic heart disease in patients with heart failure and preserved, midrange, and reduced ejection fraction: a nationwide cohort study","volume":"10","author":"Vedin","year":"2017","journal-title":"Circ Heart Fail"},{"key":"2026012115084856000_ehf212555-bib-0175","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1002\/ejhf.1058","article-title":"What have we learned about heart failure with mid-range ejection fraction one year after its introduction?","volume":"19","author":"Nauta","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"2026012115084856000_ehf212555-bib-0176","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1002\/ehf2.12131","article-title":"Who are patients classified within the new terminology of heart failure from the 2016 ESC guidelines?","volume":"4","author":"Delepaul","year":"2017","journal-title":"ESC Heart Fail"},{"key":"2026012115084856000_ehf212555-bib-0177","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1002\/ejhf.1091","article-title":"Predictors and outcomes of heart failure with mid-range ejection fraction","volume":"20","author":"Bhambhani","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"2026012115084856000_ehf212555-bib-0178","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1002\/ejhf.1298","article-title":"Is mild asymptomatic left ventricular systolic dysfunction always predictive of adverse events in high-risk populations? Insights from the DAVID-Berg study","volume":"20","author":"Gori","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"2026012115084856000_ehf212555-bib-0179","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1002\/ehf2.12283","article-title":"Characteristics and long-term prognosis of patients with heart failure and mid-range ejection fraction compared with reduced and preserved ejection fraction: a systematic review and meta-analysis","volume":"5","author":"Lauritsen","year":"2018","journal-title":"ESC Heart Fail"},{"key":"2026012115084856000_ehf212555-bib-0180","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1093\/eurheartj\/ehx564","article-title":"Beta-blockers for heart failure with reduced, mid-range, and preserved ejection fraction: an individual patient-level analysis of double-blind randomized trials","volume":"39","author":"Cleland","year":"2018","journal-title":"Eur Heart J"},{"key":"2026012115084856000_ehf212555-bib-0181","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1002\/ejhf.1149","article-title":"Heart failure with mid-range ejection fraction in CHARM: characteristics, outcomes and effect of candesartan across the entire ejection fraction spectrum","volume":"20","author":"Lund","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"2026012115084856000_ehf212555-bib-0182","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1002\/ejhf.1160","article-title":"Effect of digoxin in patients with heart failure and mid-range (borderline) left ventricular ejection fraction","volume":"20","author":"Abdul-Rahim","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"2026012115084856000_ehf212555-bib-0183","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1002\/ejhf.899","article-title":"Inotropic myocardial reserve deficiency is the predominant feature of exercise haemodynamics in cardiac amyloidosis","volume":"19","author":"Clemmensen","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"2026012115084856000_ehf212555-bib-0184","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1002\/ejhf.1039","article-title":"Intramyocardial inflammation predicts adverse outcome in patients with cardiac AL amyloidosis","volume":"20","author":"Siegismund","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"2026012115084856000_ehf212555-bib-0185","doi-asserted-by":"crossref","first-page":"2879","DOI":"10.1093\/eurheartj\/ehx350","article-title":"Unveiling transthyretin cardiac amyloidosis and its predictors among elderly patients with severe aortic stenosis undergoing transcatheter aortic valve replacement","volume":"38","author":"Castano","year":"2017","journal-title":"Eur Heart J"},{"key":"2026012115084856000_ehf212555-bib-0186","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1161\/CIRCULATIONAHA.116.021612","article-title":"Nonbiopsy diagnosis of cardiac transthyretin amyloidosis","volume":"133","author":"Gillmore","year":"2016","journal-title":"Circulation"},{"key":"2026012115084856000_ehf212555-bib-0187","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","article-title":"Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy","volume":"379","author":"Maurer","year":"2018","journal-title":"N Engl J Med"},{"key":"2026012115084856000_ehf212555-bib-0188","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1002\/ejhf.1165","article-title":"Cancer diagnosis in patients with heart failure: epidemiology, clinical implications and gaps in knowledge","volume":"20","author":"Ameri","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"2026012115084856000_ehf212555-bib-0189","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1002\/ejhf.1202","article-title":"Prevalence and prognostic impact of non-cardiac co-morbidities in heart failure outpatients with preserved and reduced ejection fraction: a community-based study","volume":"20","author":"Iorio","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"2026012115084856000_ehf212555-bib-0190","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1002\/ejhf.778","article-title":"The association of chronic kidney disease and microalbuminuria with heart failure with preserved vs. reduced ejection fraction","volume":"19","author":"Nayor","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"2026012115084856000_ehf212555-bib-0191","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1002\/ejhf.746","article-title":"Urinary levels of novel kidney biomarkers and risk of true worsening renal function and mortality in patients with acute heart failure","volume":"19","author":"Sokolski","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"2026012115084856000_ehf212555-bib-0192","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1002\/ehf2.12143","article-title":"The renal-cardiac connection in subjects with preserved ejection fraction: a population based study","volume":"4","author":"Jain","year":"2017","journal-title":"ESC Heart Fail"},{"key":"2026012115084856000_ehf212555-bib-0193","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1002\/ehf2.12185","article-title":"Impaired renal function affects clinical outcomes and management of patients with heart failure","volume":"4","author":"Jenkins","year":"2017","journal-title":"ESC Heart Fail"},{"key":"2026012115084856000_ehf212555-bib-0194","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1002\/ejhf.964","article-title":"Characteristics, treatments and 1-year prognosis of hospitalized and ambulatory heart failure patients with chronic obstructive pulmonary disease in the European Society of Cardiology Heart Failure Long-Term Registry","volume":"20","author":"Canepa","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"2026012115084856000_ehf212555-bib-0195","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1002\/ejhf.1177","article-title":"Heart-brain interactions in patients with heart failure, including takotsubo syndrome: a need to monitor autonomic sympathetic activity: reply","volume":"20","author":"Doehner","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"2026012115084856000_ehf212555-bib-0196","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1002\/ejhf.492","article-title":"Sleep-disordered breathing in heart failure","volume":"18","author":"Pearse","year":"2016","journal-title":"Eur J Heart Fail"},{"key":"2026012115084856000_ehf212555-bib-0197","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1002\/ehf2.12193","article-title":"Sleep-disordered breathing in heart failure: facts and numbers","volume":"4","author":"Pietrock","year":"2017","journal-title":"ESC Heart Fail"},{"key":"2026012115084856000_ehf212555-bib-0198","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1002\/ejhf.912","article-title":"A network analysis to compare biomarker profiles in patients with and without diabetes mellitus in acute heart failure","volume":"19","author":"Sharma","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"2026012115084856000_ehf212555-bib-0199","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1002\/ejhf.1201","article-title":"Microvascular complications in diabetes patients with heart failure and reduced ejection fraction-insights from the Beta-blocker Evaluation of Survival Trial","volume":"20","author":"Kristensen","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"2026012115084856000_ehf212555-bib-0200","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1002\/ejhf.654","article-title":"2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC)","volume":"19","author":"Zamorano","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"2026012115084856000_ehf212555-bib-0201","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1002\/ehf2.12333","article-title":"Iron deficiency in chronic heart failure: case-based practical guidance","volume":"5","author":"Lam","year":"2018","journal-title":"ESC Heart Fail"},{"key":"2026012115084856000_ehf212555-bib-0202","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1002\/ehf2.12184","article-title":"Cardiac muscle wasting in individuals with cancer cachexia","volume":"4","author":"Barkhudaryan","year":"2017","journal-title":"ESC Heart Fail"},{"key":"2026012115084856000_ehf212555-bib-0203","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1002\/ehf2.12209","article-title":"Anorexia, functional capacity, and clinical outcome in patients with chronic heart failure: results from the Studies Investigating Co-morbidities Aggravating Heart Failure (SICA-HF)","volume":"4","author":"Saitoh","year":"2017","journal-title":"ESC Heart Fail"},{"key":"2026012115084856000_ehf212555-bib-0204","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1002\/ehf2.12389","article-title":"Metabolic disorders in heart failure and cancer","volume":"5","author":"Lena","year":"2018","journal-title":"ESC Heart Fail"},{"key":"2026012115084856000_ehf212555-bib-0205","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1002\/ehf2.12387","article-title":"Skeletal muscle wasting in chronic heart failure","volume":"5","author":"Suzuki","year":"2018","journal-title":"ESC Heart Fail"},{"key":"2026012115084856000_ehf212555-bib-0206","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1002\/ejhf.1308","article-title":"The frailty syndrome and outcomes in the TOPCAT trial","volume":"20","author":"Sanders","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"2026012115084856000_ehf212555-bib-0207","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1002\/ejhf.1188","article-title":"Adiposity, body composition and ventricular-arterial stiffness in the elderly: the Atherosclerosis Risk in Communities Study","volume":"20","author":"Fernandes-Silva","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"2026012115084856000_ehf212555-bib-0208","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1002\/ejhf.1244","article-title":"Waist-to-hip ratio and mortality in heart failure","volume":"20","author":"Streng","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"2026012115084856000_ehf212555-bib-0209","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1002\/ejhf.1252","article-title":"Cancer and heart failure-more than meets the eye: common risk factors and co-morbidities","volume":"20","author":"Anker","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"2026012115084856000_ehf212555-bib-0210","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1002\/ejhf.1168","article-title":"Long-term effect of epirubicin on incidence of heart failure in women with breast cancer: insight from a randomized clinical trial","volume":"20","author":"Banke","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"2026012115084856000_ehf212555-bib-0211","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1002\/ejhf.1292","article-title":"Activity and outcomes of a cardio-oncology service in the United Kingdom-a five-year experience","volume":"20","author":"Pareek","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"2026012115084856000_ehf212555-bib-0212","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1002\/ejhf.1049","article-title":"Comparison of long-term outcome in anthracycline-related versus idiopathic dilated cardiomyopathy: a single centre experience","volume":"20","author":"Fornaro","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"2026012115084856000_ehf212555-bib-0213","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1002\/ehf2.12128","article-title":"Serum albumin level and hospital mortality in acute non-ischemic heart failure","volume":"4","author":"Ancion","year":"2017","journal-title":"ESC Heart Fail"},{"key":"2026012115084856000_ehf212555-bib-0214","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1002\/ejhf.1050","article-title":"Acutely decompensated heart failure with preserved and reduced ejection fraction present with comparable haemodynamic congestion","volume":"20","author":"Van Aelst","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"2026012115084856000_ehf212555-bib-0215","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1002\/ejhf.1323","article-title":"Heart failure in the outpatient versus inpatient setting: findings from the BIOSTAT-CHF study","volume":"21","author":"Ferreira","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"2026012115084856000_ehf212555-bib-0216","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1002\/ejhf.901","article-title":"Prevalence and prognostic importance of precipitating factors leading to heart failure hospitalization: recurrent hospitalizations and mortality","volume":"20","author":"Platz","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"2026012115084856000_ehf212555-bib-0217","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1002\/ejhf.682","article-title":"Precipitating factors and 90-day outcome of acute heart failure: a report from the intercontinental GREAT registry","volume":"19","author":"Arrigo","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"2026012115084856000_ehf212555-bib-0218","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1002\/ehf2.12083","article-title":"Effect of precipitating factors of acute heart failure on readmission and long-term mortality","volume":"3","author":"Arrigo","year":"2016","journal-title":"ESC Heart Fail"},{"key":"2026012115084856000_ehf212555-bib-0219","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1002\/ejhf.1213","article-title":"PHARMacy-based interdisciplinary program for patients with Chronic Heart Failure (PHARM-CHF): rationale and design of a randomized controlled trial, and results of the pilot study","volume":"20","author":"Laufs","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"2026012115084856000_ehf212555-bib-0220","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1002\/ejhf.1046","article-title":"Employment status at time of first hospitalization for heart failure is associated with a higher risk of death and rehospitalization for heart failure","volume":"20","author":"Rorth","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"2026012115084856000_ehf212555-bib-0221","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1002\/ejhf.709","article-title":"Prognostic burden of heart failure recorded in primary care, acute hospital admissions, or both: a population-based linked electronic health record cohort study in 2.1 million people","volume":"19","author":"Koudstaal","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"2026012115084856000_ehf212555-bib-0222","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1002\/ejhf.1020","article-title":"Aetiology, timing and clinical predictors of early vs. late readmission following index hospitalization for acute heart failure: insights from ASCEND-HF","volume":"20","author":"Fudim","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"2026012115084856000_ehf212555-bib-0223","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.jacc.2012.11.005","article-title":"Effect of serelaxin on cardiac, renal, and hepatic biomarkers in the Relaxin in Acute Heart Failure (RELAX-AHF) development program: correlation with outcomes","volume":"61","author":"Metra","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"2026012115084856000_ehf212555-bib-0224","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1002\/ejhf.872","article-title":"Organ dysfunction, injury and failure in acute heart failure: from pathophysiology to diagnosis and management. A review on behalf of the Acute Heart Failure Committee of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC)","volume":"19","author":"Harjola","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"2026012115084856000_ehf212555-bib-0225","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1002\/ejhf.1204","article-title":"Comprehensive in-hospital monitoring in acute heart failure: applications for clinical practice and future directions for research. A statement from the Acute Heart Failure Committee of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC)","volume":"20","author":"Harjola","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"2026012115084856000_ehf212555-bib-0226","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1002\/ejhf.1156","article-title":"Increased blood lactate is prevalent and identifies poor prognosis in patients with acute heart failure without overt peripheral hypoperfusion","volume":"20","author":"Zymlinski","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"2026012115084856000_ehf212555-bib-0227","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1002\/ejhf.1378","article-title":"Multi-organ dysfunction\/injury on admission identifies acute heart failure patients at high risk of poor outcome","volume":"21","author":"Zymlinski","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"2026012115084856000_ehf212555-bib-0228","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1056\/NEJMoa1801291","article-title":"Effects of serelaxin in patients with acute heart failure","volume":"381","author":"Metra","year":"2019","journal-title":"N Engl J Med"},{"key":"2026012115084856000_ehf212555-bib-0229","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1002\/ejhf.830","article-title":"Serelaxin in addition to standard therapy in acute heart failure: rationale and design of the RELAX-AHF-2 study","volume":"19","author":"Teerlink","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"2026012115084856000_ehf212555-bib-0230","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1002\/ejhf.1078","article-title":"Sudden cardiac death after acute heart failure hospital admission: insights from ASCEND-HF","volume":"20","author":"Pokorney","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"2026012115084856000_ehf212555-bib-0231","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1002\/ejhf.1131","article-title":"Association between mean systolic and diastolic blood pressure throughout the follow-up and cardiovascular events in acute myocardial infarction patients with systolic dysfunction and\/or heart failure: an analysis from the High-Risk Myocardial Infarction Database Initiative","volume":"20","author":"Ferreira","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"2026012115084856000_ehf212555-bib-0232","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1002\/ejhf.1162","article-title":"Interaction of systolic blood pressure and resting heart rate with clinical outcomes in takotsubo syndrome: insights from the International Takotsubo Registry","volume":"20","author":"Bohm","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"2026012115084856000_ehf212555-bib-0233","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1002\/ejhf.889","article-title":"Systolic blood pressure reduction during the first 24 h in acute heart failure admission: friend or foe?","volume":"20","author":"Cotter","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"2026012115084856000_ehf212555-bib-0234","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1093\/ehjci\/jew082","article-title":"Recommendations for the evaluation of left ventricular diastolic function by echocardiography: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging","volume":"17","author":"Nagueh","year":"2016","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"2026012115084856000_ehf212555-bib-0235","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1002\/ejhf.839","article-title":"Dynamic changes and prognostic value of pulmonary congestion by lung ultrasound in acute and chronic heart failure: a systematic review","volume":"19","author":"Platz","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"2026012115084856000_ehf212555-bib-0236","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1002\/ejhf.1383","article-title":"Prevalence, pattern and clinical relevance of ultrasound indices of congestion in outpatients with heart failure","volume":"21","author":"Pellicori","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"2026012115084856000_ehf212555-bib-0237","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1002\/ehf2.12150","article-title":"Comparative accuracy of NT-proBNP and MR-proANP for the diagnosis of acute heart failure in dyspnoeic patients","volume":"4","author":"Darche","year":"2017","journal-title":"ESC Heart Fail"},{"key":"2026012115084856000_ehf212555-bib-0238","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1002\/ehf2.12191","article-title":"Proposal for heart failure progression based on the 'chloride theory': worsening heart failure with increased vs. non-increased serum chloride concentration","volume":"4","author":"Kataoka","year":"2017","journal-title":"ESC Heart Fail"},{"key":"2026012115084856000_ehf212555-bib-0239","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1002\/ejhf.1247","article-title":"Low serum chloride in patients with chronic heart failure: clinical associations and prognostic significance","volume":"20","author":"Cuthbert","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"2026012115084856000_ehf212555-bib-0240","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.116.003109","article-title":"Hypochloremia, Diuretic Resistance, and Outcome in Patients With Acute Heart Failure","volume":"9","author":"Ter Maaten","year":"2016","journal-title":"Circ Heart Fail"},{"key":"2026012115084856000_ehf212555-bib-0241","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1002\/ejhf.1229","article-title":"Perturbations in serum chloride homeostasis in heart failure with preserved ejection fraction: insights from TOPCAT","volume":"20","author":"Grodin","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"2026012115084856000_ehf212555-bib-0242","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1002\/ejhf.667","article-title":"Impact of haemoconcentration during acute heart failure therapy on mortality and its relationship with worsening renal function","volume":"19","author":"Breidthardt","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"2026012115084856000_ehf212555-bib-0243","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.115.002845","article-title":"Combining diuretic response and hemoconcentration to predict rehospitalization after admission for acute heart failure","volume":"9","author":"Ter Maaten","year":"2016","journal-title":"Circ Heart Fail"},{"key":"2026012115084856000_ehf212555-bib-0244","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1002\/ehf2.12188","article-title":"Persistent high blood urea nitrogen level is associated with increased risk of cardiovascular events in patients with acute heart failure","volume":"4","author":"Jujo","year":"2017","journal-title":"ESC Heart Fail"},{"key":"2026012115084856000_ehf212555-bib-0245","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1002\/ejhf.932","article-title":"Heart failure oral therapies at discharge are associated with better outcome in acute heart failure: a propensity-score matched study","volume":"20","author":"Gayat","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"2026012115084856000_ehf212555-bib-0246","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1002\/ejhf.991","article-title":"Long-term safety of intravenous cardiovascular agents in acute heart failure: results from the European Society of Cardiology Heart Failure Long-Term Registry","volume":"20","author":"Mebazaa","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"2026012115084856000_ehf212555-bib-0247","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1002\/ejhf.897","article-title":"A Phase 2a dose-escalation study of the safety, tolerability, pharmacokinetics and haemodynamic effects of BMS-986231 in hospitalized patients with heart failure with reduced ejection fraction","volume":"19","author":"Tita","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"2026012115084856000_ehf212555-bib-0248","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1002\/ejhf.1504","article-title":"Rationale and design for the development of a novel nitroxyl donor in patients with acute heart failure","volume":"21","author":"Felker","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"2026012115084856000_ehf212555-bib-0249","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1002\/ejhf.757","article-title":"Renal tubular resistance is the primary driver for loop diuretic resistance in acute heart failure","volume":"19","author":"Ter Maaten","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"2026012115084856000_ehf212555-bib-0250","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1002\/ejhf.1307","article-title":"Rationale and design of the ADVOR (Acetazolamide in Decompensated Heart Failure with Volume Overload) trial","volume":"20","author":"Mullens","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"2026012115084856000_ehf212555-bib-0251","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1002\/ejhf.850","article-title":"Modalities and effects of left ventricle unloading on extracorporeal life support: a review of the current literature","volume":"19","author":"Meani","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"2026012115084856000_ehf212555-bib-0252","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1002\/ejhf.668","article-title":"Concomitant implantation of Impella((R)) on top of veno-arterial extracorporeal membrane oxygenation may improve survival of patients with cardiogenic shock","volume":"19","author":"Pappalardo","year":"2017","journal-title":"Eur J Heart Fail"}],"container-title":["ESC Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fehf2.12555","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ehf2.12555","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/ehf2.12555","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/6\/6\/1105\/66136407\/eschf_6_6_1105.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/6\/6\/1105\/66136407\/eschf_6_6_1105.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T20:11:28Z","timestamp":1769026288000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eschf\/article\/6\/6\/1105\/8403504"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,1]]},"references-count":252,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2020,1,29]]},"published-print":{"date-parts":[[2019,12,1]]}},"URL":"https:\/\/doi.org\/10.1002\/ehf2.12555","relation":{},"ISSN":["2055-5822"],"issn-type":[{"value":"2055-5822","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,12]]},"published":{"date-parts":[[2019,12,1]]},"assertion":[{"value":"2019-10-25","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-10-30","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-01-29","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}